Antimetastatic role of Smad4 signaling in colorectal cancer.

Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL, Datta PK
Gastroenterology. 2010 138 (3): 969-80.e1-3

PMID: 19909744 · PMCID: PMC2831103 · DOI:10.1053/j.gastro.2009.11.004

BACKGROUND & AIMS - Transforming growth factor (TGF)-beta signaling occurs through Smads 2/3/4, which translocate to the nucleus to regulate transcription; TGF-beta has tumor-suppressive effects in some tumor models and pro-metastatic effects in others. In patients with colorectal cancer (CRC), mutations or reduced levels of Smad4 have been correlated with reduced survival. However, the function of Smad signaling and the effects of TGF-beta-receptor kinase inhibitors have not been analyzed during CRC metastasis. We investigated the role of TGF-beta/Smad signaling in CRC progression.

METHODS - We evaluated the role of TGF-beta/Smad signaling on cell proliferation, migration, invasion, tumorigenicity, and metastasis in Smad4-null colon carcinoma cell lines (MC38 and SW620) and in those that transgenically express Smad4. We also determined the effects of a TGF-beta-receptor kinase inhibitor (LY2109761) in CRC tumor progression and metastasis in mice.

RESULTS - TGF-beta induced migration/invasion, tumorigenicity, and metastasis of Smad4-null MC38 and SW620 cells; incubation with LY2109761 reversed these effects. In mice, LY2109761 blocked metastasis of CRC cells to liver, inducing cancer cell expression of E-cadherin and reducing the expression of the tumorigenic proteins matrix metalloproteinase-9, nm23, urokinase plasminogen activator, and cyclooxygenase-2. Transgenic expression of Smad4 significantly reduced the oncogenic potential of MC38 and SW620 cells; in these transgenic cells, TGF-beta had tumor suppressor, rather than tumorigenic, effects.

CONCLUSIONS - TGF-beta/Smad signaling suppresses progression and metastasis of CRC cells and tumors in mice. Loss of Smad4 might underlie the functional shift of TGF-beta from a tumor suppressor to a tumor promoter; inhibitors of TGF-beta signaling might be developed as CRC therapeutics.

Copyright 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.

MeSH Terms (27)

Adenocarcinoma Animals Antineoplastic Agents Cadherins Cell Line, Tumor Cell Movement Cell Proliferation Colorectal Neoplasms Female Humans Liver Neoplasms Matrix Metalloproteinase 9 Mice Mice, Inbred C57BL Mice, Nude Neoplasm Invasiveness NM23 Nucleoside Diphosphate Kinases Protein Kinase Inhibitors Pyrazoles Pyrroles Receptors, Transforming Growth Factor beta Signal Transduction Smad4 Protein Time Factors Transfection Transforming Growth Factor beta1 Urokinase-Type Plasminogen Activator

Connections (2)

This publication is referenced by other Labnodes entities: